CY1120908T1 - Μεθοδοι και συστηματα για τον καθαρισμο της μη συμπλεγμενης νευροτοξινης της αλλαντιασης - Google Patents
Μεθοδοι και συστηματα για τον καθαρισμο της μη συμπλεγμενης νευροτοξινης της αλλαντιασηςInfo
- Publication number
- CY1120908T1 CY1120908T1 CY181100988T CY181100988T CY1120908T1 CY 1120908 T1 CY1120908 T1 CY 1120908T1 CY 181100988 T CY181100988 T CY 181100988T CY 181100988 T CY181100988 T CY 181100988T CY 1120908 T1 CY1120908 T1 CY 1120908T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- systems
- neurotoxin
- chealth
- cleansing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Παρουσιάζονται μέθοδοι και συστήματα για τον χρωματογραφικό καθαρισμό μιας νευροτοξίνης της αλλαντίασης. Αυτές οι μέθοδοι και τα συστήματα καθιστούν δυνατό τον αποτελεσματικό καθαρισμό μιας μη συμπλεγμένης μορφής της νευροτοξίνης της αλλαντίασης με υψηλό καθαρισμό και απόδοση, η οποία μπορεί να χρησιμοποιηθεί ως ενεργό συστατικό φαρμακευτικών σκευασμάτων.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25381009P | 2009-10-21 | 2009-10-21 | |
PCT/US2010/053389 WO2011050072A1 (en) | 2009-10-21 | 2010-10-20 | Methods and systems for purifying non-complexed botulinum neurotoxin |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1120908T1 true CY1120908T1 (el) | 2019-12-11 |
Family
ID=43879799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY181100988T CY1120908T1 (el) | 2009-10-21 | 2018-09-25 | Μεθοδοι και συστηματα για τον καθαρισμο της μη συμπλεγμενης νευροτοξινης της αλλαντιασης |
Country Status (23)
Country | Link |
---|---|
US (5) | US20110092682A1 (el) |
EP (1) | EP2490986B2 (el) |
JP (1) | JP5951490B2 (el) |
KR (1) | KR101819129B1 (el) |
CN (2) | CN104961812B (el) |
AU (1) | AU2010310749B2 (el) |
BR (1) | BR112012009227A2 (el) |
CA (1) | CA2773396C (el) |
CO (1) | CO6551670A2 (el) |
CY (1) | CY1120908T1 (el) |
DK (1) | DK2490986T4 (el) |
ES (1) | ES2688065T3 (el) |
HK (2) | HK1175453A1 (el) |
HR (1) | HRP20181869T1 (el) |
HU (1) | HUE041599T2 (el) |
IL (2) | IL218532A (el) |
LT (1) | LT2490986T (el) |
MX (3) | MX2012004703A (el) |
PL (1) | PL2490986T3 (el) |
PT (1) | PT2490986T (el) |
RS (1) | RS58006B1 (el) |
SI (1) | SI2490986T1 (el) |
WO (1) | WO2011050072A1 (el) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102300584A (zh) | 2008-12-31 | 2011-12-28 | 雷文斯治疗公司 | 可注射的肉毒杆菌毒素制剂 |
MX366344B (es) * | 2009-06-25 | 2019-07-05 | Revance Therapeutics Inc | Formulaciones de toxina botulinica libres de albumina. |
US8129139B2 (en) | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
PT2490986T (pt) * | 2009-10-21 | 2018-11-13 | Revance Therapeutics Inc | Métodos e sistemas para purificar neurotoxina botulínica não complexada |
KR101134146B1 (ko) | 2010-05-31 | 2012-04-19 | 메덱스젠 주식회사 | 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 |
CA2918233C (en) * | 2013-07-30 | 2022-08-30 | Merz Pharma Gmbh & Co. Kgaa | Process for preparing a highly pure neurotoxic component of a botulinum toxin and uses thereof |
KR101339349B1 (ko) * | 2013-08-02 | 2013-12-09 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
US9480731B2 (en) | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
GB201517450D0 (en) * | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
KR101775682B1 (ko) * | 2015-11-30 | 2017-09-06 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
KR102463881B1 (ko) | 2016-10-04 | 2022-11-07 | (주)메디톡스 | 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법 |
US20210162026A1 (en) | 2017-08-28 | 2021-06-03 | Revance Therapeutics, Inc. | Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders |
CN113056478A (zh) * | 2018-12-21 | 2021-06-29 | 一般财团法人阪大微生物病研究会 | 肉毒毒素的制造方法 |
KR102516203B1 (ko) * | 2019-04-15 | 2023-03-30 | (주)제테마 | 보툴리눔 독소의 제조방법 |
KR102516204B1 (ko) * | 2019-04-15 | 2023-03-30 | (주)제테마 | 보툴리눔 독소의 정제방법 |
US10851363B1 (en) * | 2019-05-22 | 2020-12-01 | Boke Zhang | Multilayer nano-cell containing biomolecules |
KR20230009178A (ko) * | 2021-07-08 | 2023-01-17 | 주식회사 파마리서치바이오 | 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법 |
KR102512757B1 (ko) * | 2021-07-22 | 2023-03-22 | (주)이니바이오 | 정제 수율이 향상된 보툴리눔 독소 복합체 정제방법 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US796419A (en) | 1904-07-18 | 1905-08-08 | Carl Halbig | Doll-head. |
SE303567B (el) * | 1959-02-17 | 1968-09-02 | Behringwerke Ag | |
US7214787B1 (en) * | 1993-09-21 | 2007-05-08 | United States Of America As Represented By The Secretary Of The Army | Recombinant vaccine against botulinum neurotoxin |
US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
EP1053014A4 (en) * | 1998-01-26 | 2004-11-10 | Univ Massachusetts | BIOLOGICALLY ACTIVE HEMAGGLUTININE TYPE A i (STRIDIUM BOTULINUM) AND METHOD FOR ITS USE |
TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
DE19925739A1 (de) * | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
GB9921592D0 (en) * | 1999-09-13 | 1999-11-17 | Microbiological Res Authority | Preparation of highly pure toxin fragments |
IL154044A0 (en) * | 2000-07-21 | 2003-07-31 | Essentia Biosystems Inc | Multi-component pharmaceutical compositions containing a complex of a positively charged backbone and a negatively charged backbone and methods for the preparation thereof |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
JP2003009897A (ja) | 2001-07-03 | 2003-01-14 | Keiji Oguma | ボツリヌス毒素の分離・精製法 |
GB2386246B (en) | 2001-11-01 | 2005-06-29 | Marconi Applied Techn Ltd | Electron beam tube apparatus |
ATE494367T1 (de) * | 2002-12-18 | 2011-01-15 | Hoffmann La Roche | Rekombinante desoxyribonuclease i aus rinder- pankreas mit hoher spezifischer aktivität |
KR100498964B1 (ko) | 2003-03-05 | 2005-07-01 | 삼성전자주식회사 | 이동단말에서의 전자파 흡수율 제어 방법 및 장치 |
AU2003271835A1 (en) * | 2003-06-06 | 2005-01-04 | Avecia Limited | Process for the separation of proteins |
US7354740B2 (en) * | 2003-09-25 | 2008-04-08 | Allergan, Inc. | Animal product free system and process for purifying a botulinum toxin |
US7452697B2 (en) * | 2003-09-25 | 2008-11-18 | Allergan, Inc. | Chromatographic method and system for purifying a botulinum toxin |
CA2548378A1 (en) * | 2003-12-30 | 2005-07-14 | Bharat Biotech International Limited | A process for the preparation and purification of recombinant proteins |
KR20050074806A (ko) * | 2004-01-14 | 2005-07-19 | 팜텍(주) | 결정형 보툴리늄 독소의 제조방법 |
CA3031270A1 (en) * | 2004-03-03 | 2005-12-22 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
EP1729821B1 (en) * | 2004-03-03 | 2013-07-17 | ReVance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
CA2612205C (en) * | 2005-06-17 | 2012-07-10 | Merz Pharma Gmbh & Co. Kgaa | Apparatus and process for the fermentative production of biological active compounds |
US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
AR061669A1 (es) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
PT2085093E (pt) * | 2006-10-27 | 2015-06-26 | Chemo Sero Therapeut Res Inst | Preparação que contém uma toxina botulínica tipo a altamente purificada derivada de um agente patogénico do botulismo infantil |
CN100588706C (zh) * | 2007-04-06 | 2010-02-10 | 常州千红生化制药股份有限公司 | 纯化弹性蛋白酶的方法 |
WO2008145358A1 (en) * | 2007-06-01 | 2008-12-04 | Merz Pharma Gmbh & Co. Kgaa | Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin in solid form |
JP5344558B2 (ja) * | 2008-10-31 | 2013-11-20 | 国立大学法人 東京医科歯科大学 | カチオン性ナノゲルを用いる粘膜ワクチン |
CN102300584A (zh) * | 2008-12-31 | 2011-12-28 | 雷文斯治疗公司 | 可注射的肉毒杆菌毒素制剂 |
US8440204B2 (en) * | 2009-04-30 | 2013-05-14 | Wisconsin Alumni Research Foundation | Subtype of Closteridium botulinum neurotoxin type A and uses thereof |
MX366344B (es) * | 2009-06-25 | 2019-07-05 | Revance Therapeutics Inc | Formulaciones de toxina botulinica libres de albumina. |
US8129139B2 (en) * | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
JP2011074025A (ja) * | 2009-09-30 | 2011-04-14 | Chemo-Sero-Therapeutic Research Inst | ボツリヌス毒素の精製方法 |
PT2490986T (pt) * | 2009-10-21 | 2018-11-13 | Revance Therapeutics Inc | Métodos e sistemas para purificar neurotoxina botulínica não complexada |
US8440104B2 (en) * | 2009-10-21 | 2013-05-14 | General Electric Company | Kimzeyite garnet phosphors |
WO2013181576A2 (en) * | 2012-06-01 | 2013-12-05 | Momenta Pharmaceuticals, Inc. | Methods of evaluating and making biologics |
CA2889833A1 (en) * | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and methods for safe treatment of rhinitis |
GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
GB201517450D0 (en) * | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
WO2017075468A1 (en) * | 2015-10-29 | 2017-05-04 | Revance Therapeutics, Inc. | Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect |
KR101775682B1 (ko) * | 2015-11-30 | 2017-09-06 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
EP3624819A4 (en) * | 2017-05-18 | 2021-03-24 | Revance Therapeutics, Inc. | METHOD OF TREATMENT OF CERVICAL DYSTONIA |
-
2010
- 2010-10-20 PT PT10825598T patent/PT2490986T/pt unknown
- 2010-10-20 SI SI201031746T patent/SI2490986T1/sl unknown
- 2010-10-20 LT LTEP10825598.5T patent/LT2490986T/lt unknown
- 2010-10-20 MX MX2012004703A patent/MX2012004703A/es active IP Right Grant
- 2010-10-20 ES ES10825598.5T patent/ES2688065T3/es active Active
- 2010-10-20 US US12/908,647 patent/US20110092682A1/en not_active Abandoned
- 2010-10-20 MX MX2015011592A patent/MX365496B/es unknown
- 2010-10-20 WO PCT/US2010/053389 patent/WO2011050072A1/en active Application Filing
- 2010-10-20 EP EP10825598.5A patent/EP2490986B2/en active Active
- 2010-10-20 PL PL10825598T patent/PL2490986T3/pl unknown
- 2010-10-20 KR KR1020127012224A patent/KR101819129B1/ko active IP Right Grant
- 2010-10-20 RS RS20181330A patent/RS58006B1/sr unknown
- 2010-10-20 HU HUE10825598A patent/HUE041599T2/hu unknown
- 2010-10-20 DK DK10825598.5T patent/DK2490986T4/da active
- 2010-10-20 JP JP2012535338A patent/JP5951490B2/ja active Active
- 2010-10-20 US US13/394,506 patent/US20120196349A1/en not_active Abandoned
- 2010-10-20 CN CN201510173705.8A patent/CN104961812B/zh active Active
- 2010-10-20 CN CN201080045567.0A patent/CN102666396B/zh active Active
- 2010-10-20 CA CA2773396A patent/CA2773396C/en active Active
- 2010-10-20 BR BR112012009227A patent/BR112012009227A2/pt not_active IP Right Cessation
- 2010-10-20 AU AU2010310749A patent/AU2010310749B2/en active Active
-
2012
- 2012-03-07 IL IL218532A patent/IL218532A/en active IP Right Grant
- 2012-04-20 MX MX2019006519A patent/MX2019006519A/es unknown
- 2012-04-30 CO CO12070154A patent/CO6551670A2/es not_active Application Discontinuation
-
2013
- 2013-02-27 HK HK13102459.5A patent/HK1175453A1/xx unknown
-
2015
- 2015-07-10 US US14/796,235 patent/US9469849B2/en active Active
-
2016
- 2016-04-05 HK HK16103844.4A patent/HK1215951A1/zh unknown
- 2016-10-17 US US15/295,134 patent/US20170029795A1/en not_active Abandoned
- 2016-10-25 IL IL248486A patent/IL248486A0/en unknown
-
2018
- 2018-09-25 CY CY181100988T patent/CY1120908T1/el unknown
- 2018-11-08 HR HRP20181869TT patent/HRP20181869T1/hr unknown
-
2019
- 2019-12-02 US US16/700,728 patent/US11466262B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120908T1 (el) | Μεθοδοι και συστηματα για τον καθαρισμο της μη συμπλεγμενης νευροτοξινης της αλλαντιασης | |
CY1125155T1 (el) | Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης | |
CY1123208T1 (el) | Κυκλικα παραγωγα εστερων βορονικου οξεος, μεθοδος για την παρασκευη και θεραπευτικες χρησεις αυτων | |
WO2013078170A8 (en) | Purification of anti-c-met antibodies | |
BR112015004467A2 (pt) | método para controlar a heterogeneidade de proteínas | |
SG10201804869UA (en) | Purification of biological molecules | |
MX348003B (es) | Metodos y medios para modificar un genoma vegetal. | |
BRPI0917993B8 (pt) | composições de célula-tronco mesenquimal purificada | |
IN2012DN00801A (el) | ||
MX368142B (es) | Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab. | |
MX2015008875A (es) | Metodos para la purificacion de arilsulfatasa a. | |
EA202090044A1 (ru) | Очистка идуронат-2-сульфатазы | |
CY1117288T1 (el) | Παραγωγα 2-οξο-1-πυρρολιδινυλ ιμιδαζοθειαδιαζολης | |
IN2014DN00161A (el) | ||
UY33200A (es) | Derivados de ácido 3-heteroaroilamino-propiónico sustituidos con oxígeno y su uso como productos farmacéuticos | |
BR112015007422A2 (pt) | novos compostos farmacêuticos | |
MX2013013649A (es) | Compuestos de quinona para tratar enfermedades mediadas por ape1. | |
BR112014008616A2 (pt) | compostos antivirais | |
CY1119064T1 (el) | Ινωδολυτικες συνθεσεις οι οποιες περιεχουν βρωμελαϊνη και ναττοκιναση για την προληψη και αγωγη φλεβοθρομβωτικων καταστασεων | |
BR112014016803A2 (pt) | amidas macrocíclicas como inibidoras de protease | |
BR112012017393A2 (pt) | derivados de 2,5,7-oxazolpirimidina substituída | |
TR201009167A2 (tr) | Sefalosporin içeren farmasötik granüller. | |
MX355719B (es) | Composicion farmaceutica en forma de una suspension oral que comprende una fraccion flavonoica y goma de xantano. | |
AU2012345659A8 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
WO2011093831A3 (en) | Effervescent formulations comprising cefprozil as active agent |